BPC-157 (Body Protective Compound) for Parkinson's Disease

Also known as: Body Protective Compound-157, Pentadecapeptide BPC 157

BPC-157's dopaminergic system effects and neuroprotective signaling are relevant to Parkinson's neuronal preservation.

Mechanism of Action

BPC-157 interacts with the dopaminergic system, counteracting dopamine receptor agonist and antagonist effects in animal models. It reduces oxidative stress, promotes angiogenesis in the nigrostriatal pathway, and activates JAK-2/STAT-3 survival signaling relevant to dopaminergic neuron preservation.

General mechanism: Pentadecapeptide that upregulates growth factor receptors, modulates nitric oxide, and activates JAK-2/STAT-3 for tissue repair and neuroprotection.

Current Evidence

Animal studies show BPC-157 counteracts haloperidol-induced catalepsy and modulates dopamine turnover. Direct neuroprotective effects on dopaminergic neurons demonstrated in oxidative stress models. Human trials for Parkinson's are lacking.

Clinical Status: Preclinical for Parkinson's. No clinical trials specific to PD.

Safety Profile

Excellent preclinical safety. No significant toxicity reported. Limited human safety data from controlled trials.

Key Research Questions

Frequently Asked Questions

Is BPC-157 safe for humans?

BPC-157 is a synthetic pentadecapeptide derived from human gastric juice. It has an excellent safety profile in animal studies with no reported toxicity even at high doses. Human clinical trials are limited. It's used in research and by some clinicians for tissue repair, but is not FDA-approved for any indication.

BPC-157 dosage for neuroprotection

Research dosages in animal studies translate to approximately 200-800mcg/day in humans (subcutaneous or oral). Some practitioners use 250-500mcg twice daily. Oral BPC-157 (stable gastric pentadecapeptide) may be sufficient for gut-brain axis effects. No standardized human dosing exists.

View glossary entry →

← Back to Parkinson's Disease Research